Contact Us
Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025
Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Report 2025
Item added to cart!

Report Price : $4490.00

Pages : 250

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025

By Drug Type (GnRH Agonists, Leuprorelin, Goserelin, Triptorelin, Histrelin, Buserelin, GnRH Antagonists, Degarelix, Abarelix, Other Drug Types), By Application (Gynecology, Oncology, Other Applications), By End-User (Hospitals, Specialty Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

• Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs market size has reached to $1.57 billion in 2024

• Expected to grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%

• Growth Driver: Surge In Ovarian And Prostate Cancers Fueling The Growth Of The Market Due To Rising Life Expectancy And Hormone Sensitivity

• Market Trend: Companies Drive Innovation With Oral GnRH Antagonists To Enhance Prostate Cancer Treatment

North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market?

Gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs are synthetic medications that regulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. GnRH agonists initially stimulate and then suppress LH and FSH production over time, while GnRH antagonists directly block GnRH receptors, causing an immediate decrease in hormone levels.

The main drug types of gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs include GnRH agonists, leuprorelin, goserelin, triptorelin, histrelin, buserelin, gonadotropin-releasing hormone (GnRH) antagonists, degarelix, abarelix, and others. GnRH agonists are synthetic drugs that act like the natural hormone GnRH, causing the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) at first, but with continued use, they eventually suppress these hormones and sex hormone production. The various applications involved are Gynecology, oncology, and others, and are used by several end-users such as hospitals, specialty clinics, and others.

Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Size 2025 And Growth Rate?

The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size has grown strongly in recent years. It will grow from $1.57 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing prevalence of hormone-related disorders, rising incidence of prostate and breast cancer, growing awareness about reproductive health, increasing demand for assisted reproductive technologies, and rising adoption of hormone therapies in endometriosis and uterine fibroids.

What Is The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth Forecast?

The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing preference for minimally invasive treatments, rising awareness of women’s health issues, growing availability of combination therapies, increasing healthcare access in developing regions, and rising pipeline of innovative formulations. Major trends in the forecast period include advancement in oral GnRH antagonist formulations, innovation in combination therapies with hormonal add-back, integration of digital health tools in reproductive treatment monitoring, advancement in clinical trial designs for faster approvals, and integration of telemedicine in hormone therapy.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Segmented?

1) By Drug Type: GnRH Agonists, Leuprorelin, Goserelin, Triptorelin, Histrelin, Buserelin, GnRH Antagonists, Degarelix, Abarelix, Other Drug Types

2) By Application: Gynecology, Oncology, Other Applications

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By GnRH Agonists: Deslorelin, Gonadorelin, Zoladex Long-Acting Goserelin Variant, Lupron Depot-Ped, Sustained-Release Microsphere Formulations

2) By Leuprorelin: Depot Injection, Implant, Combination Therapy Formulations

3) By Goserelin: Subcutaneous Implant, Oncology-Specific Formulation, Gynecology-Specific Formulation

4) By Triptorelin: Intramuscular Injection, Long-Acting (1-, 3-, 6-Month) Depot, Fertility Treatment Formulation

5) By Histrelin: Subcutaneous Implant, Pediatric (Precocious Puberty) Formulation, Adult Prostate Cancer-Specific Version

6) By Buserelin: Nasal Spray, Subcutaneous Injection, In Vitro Fertilization And Fertility Cycle Formulations

7) By GnRH Antagonists: Teverelix DP, Elagolix, Relugolix, Ganirelix, Linzagolix

8) By Degarelix: Subcutaneous Injection, Monthly Dosing, Prostate Cancer-Specific Formulation

9) By Abarelix: Intramuscular Injection, Advanced Prostate Cancer, Short-Acting Formulation

10) By Other Drug Types: Subcutaneous Injection, In Vitro Fertilization-Specific Use, Multiple Dosing Regimens

What Is Driving The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market? Surge In Ovarian And Prostate Cancers Fueling The Growth Of The Market Due To Rising Life Expectancy And Hormone Sensitivity

The increasing prevalence of ovarian and prostate cancers is expected to propel the growth of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market going forward. Ovarian and prostate cancers are hormone-sensitive tumors influenced by estrogen and testosterone and are often treated using hormone-regulating therapies such as GnRH agonists or antagonists. The rise in ovarian and prostate cancers is due to increasing life expectancy, as the risk of developing these hormone-sensitive cancers grows with age. Gonadotropin-releasing hormone (GnRH) agonists and antagonists help treat ovarian and prostate cancers by suppressing the production of sex hormones such as estrogen and testosterone, which fuel the growth of these hormone-sensitive tumors. For instance, in 2023, according to Cancer Australia, an Australian government agency, approximately 1,786 new cases of ovarian cancer are expected to be diagnosed in Australia. Additionally, women have about a 1 in 87 chance (or 1.2% risk) of being diagnosed with ovarian cancer by the age of 85. Therefore, increasing prevalence of ovarian and prostate cancers is driving the growth of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs industry.

Who Are The Major Players In The Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market?

Major companies operating in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market are Pfizer Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Intas Pharmaceuticals Limited, Sumitomo Pharma Co. Ltd., Ipsen S.A., Dr. Reddy's Laboratories Limited, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Zydus Lifesciences Limited, Gland Pharma Limited, Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Aska Pharmaceutical Co. Ltd., Ferring International Center S.A., Tolmar Inc., Debiopharm International SA, TerSera Therapeutics LLC, TiumBio Co. Ltd.

What Are The Key Trends Of The Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market? Companies Drive Innovation With Oral GnRH Antagonists To Enhance Prostate Cancer Treatment

Major companies operating in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market are focusing on developing innovative solutions, such as oral gonadotropin-releasing hormone (GnRH) receptor antagonists, to improve patient convenience, enhance treatment adherence, and reduce the need for injectable therapies. An oral gonadotropin-releasing hormone (GnRH) receptor antagonist is a pill that blocks GnRH receptors to quickly lower sex hormone levels, helping treat hormone-related conditions such as prostate cancer and endometriosis. For instance, in March 2024, Sumitomo Pharma Co. Ltd., a Japan-based pharmaceutical company, announced that ORGOVYX (relugolix), the first and only oral androgen deprivation therapy (ADT) for advanced prostate cancer, is now available in Canada following Health Canada's approval. ORGOVYX is a once-daily oral gonadotropin-releasing hormone (GnRH) receptor antagonist that suppresses testosterone production, a key driver of prostate cancer progression. Its approval was based on the Phase 3 HERO study, which demonstrated effective and sustained testosterone suppression, a reduction in major cardiovascular events, and comparable castration resistance-free survival to standard injectable therapies.

Need data on a specific region in this market?

What Are Latest Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market? Debiopharm Partners With Aspen To Expand Access To Prostate Cancer Treatment In South Africa

In February 2022, Debiopharm Group, a Switzerland-based biopharmaceutical company, partnered with Aspen Pharmacare Holdings Limited to advance treatment of locally advanced and metastatic hormone-dependent prostate cancer. The collaboration between Debiopharm and Aspen aims to increase access to Debiopharm’s GnRH drug, Trelstar, in South Africa, providing effective hormone therapy to patients with advanced prostate cancer by suppressing testosterone and slowing disease progression. Aspen Pharmacare Holdings Limited is a South Africa-based company that manufactures gonadotropin-releasing hormone (GnRH) agonists.

What Is The Regional Outlook For The Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market?

North America was the largest region in the acute care telemedicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Care Telemedicine Market?

The acute care telemedicine market includes revenues earned by entities by providing services like virtual emergency care, remote intensive care unit monitoring, tele-stroke evaluations, virtual hospitalist support, and real-time specialist consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Industry?

The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including the global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market. This market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.73 billion
Revenue Forecast In 2034 $2.49 billion
Growth Rate CAGR of 9.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered Drug Type, Application, End-User, GnRH Agonists, Leuprorelin, Goserelin, Triptorelin, Histrelin, Buserelin, GnRH Antagonists, Degarelix, Abarelix, Other Drug Types
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Intas Pharmaceuticals Limited, Sumitomo Pharma Co. Ltd., Ipsen S.A., Dr. Reddy's Laboratories Limited, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Zydus Lifesciences Limited, Gland Pharma Limited, Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Aska Pharmaceutical Co. Ltd., Ferring International Center S.A., Tolmar Inc., Debiopharm International SA, TerSera Therapeutics LLC, TiumBio Co. Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Characteristics

3. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Trends And Strategies

4. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth Rate Analysis

5.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Total Addressable Market (TAM)

6. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Segmentation

6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

GnRH Agonists

Leuprorelin

Goserelin

Triptorelin

Histrelin

Buserelin

GnRH Antagonists

Degarelix

Abarelix

Other Drug Types

6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gynecology

Oncology

Other Applications

6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Other End-Users

6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Deslorelin

Gonadorelin

Zoladex Long-Acting Goserelin Variant

Lupron Depot-Ped

Sustained-Release Microsphere Formulations

6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depot Injection

Implant

Combination Therapy Formulations

6.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Subcutaneous Implant

Oncology-Specific Formulation

Gynecology-Specific Formulation

6.7. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Triptorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intramuscular Injection

Long-Acting (1-, 3-, 6-Month) Depot

Fertility Treatment Formulation

6.8. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Subcutaneous Implant

Pediatric (Precocious Puberty) Formulation

Adult Prostate Cancer-Specific Version

6.9. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Buserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Nasal Spray

Subcutaneous Injection

In Vitro Fertilization And Fertility Cycle Formulations

6.10. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Teverelix DP

Elagolix

Relugolix

Ganirelix

Linzagolix

6.11. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Degarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Subcutaneous Injection

Monthly Dosing

Prostate Cancer-Specific Formulation

6.12. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Abarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intramuscular Injection

Advanced Prostate Cancer

Short-Acting Formulation

6.13. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Subcutaneous Injection

In Vitro Fertilization-Specific Use

Multiple Dosing Regimens

7. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Regional And Country Analysis

7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

8.1. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

19.1. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

25.1. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview

29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Landscape And Company Profiles

30.1. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Landscape

30.2. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Other Major And Innovative Companies

31.1. Intas Pharmaceuticals Limited

31.2. Sumitomo Pharma Co. Ltd.

31.3. Ipsen S.A.

31.4. Dr. Reddy's Laboratories Limited

31.5. Cipla Limited

31.6. Gedeon Richter Plc

31.7. Lupin Limited

31.8. Zydus Lifesciences Limited

31.9. Gland Pharma Limited

31.10. Bachem Holding AG

31.11. Kissei Pharmaceutical Co. Ltd.

31.12. Aska Pharmaceutical Co. Ltd.

31.13. Ferring International Center S.A.

31.14. Tolmar Inc.

31.15. Debiopharm International SA

32. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

34. Recent Developments In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market

35. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market High Potential Countries, Segments and Strategies

35.1 Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Triptorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Buserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Degarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Abarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Asia-Pacific, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Asia-Pacific, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: China, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: China, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: India, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: India, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Japan, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Japan, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Australia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Australia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Indonesia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Indonesia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: South Korea, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: South Korea, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Western Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Western Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: UK, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: UK, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Germany, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Germany, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: France, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: France, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Italy, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Italy, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Spain, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Spain, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Eastern Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Eastern Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Russia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Russia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: North America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: North America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: USA, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: USA, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Canada, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Canada, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: South America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: South America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Brazil, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Brazil, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Middle East, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Middle East, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Africa, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 83: Africa, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 84: Pfizer Inc. Financial Performance
  • Table 85: AbbVie Inc. Financial Performance
  • Table 86: AstraZeneca plc Financial Performance
  • Table 87: Takeda Pharmaceutical Company Limited Financial Performance
  • Table 88: Merck KGaA Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Triptorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Buserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Degarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Abarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Asia-Pacific, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Asia-Pacific, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: China, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: China, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: India, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: India, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Japan, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Japan, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Australia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Australia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Indonesia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Indonesia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: South Korea, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: South Korea, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Western Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Western Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: UK, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: UK, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Germany, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Germany, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: France, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: France, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Italy, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Italy, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Spain, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Spain, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Eastern Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Eastern Europe, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Russia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Russia, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: North America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: North America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: USA, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: USA, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Canada, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Canada, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: South America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: South America, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Brazil, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Brazil, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Middle East, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Middle East, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Africa, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 83: Africa, Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 84: Pfizer Inc. Financial Performance
  • Figure 85: AbbVie Inc. Financial Performance
  • Figure 86: AstraZeneca plc Financial Performance
  • Figure 87: Takeda Pharmaceutical Company Limited Financial Performance
  • Figure 88: Merck KGaA Financial Performance

Frequently Asked Questions

Gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs are synthetic medications that regulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. GnRH agonists initially stimulate and then suppress LH and FSH production over time, while GnRH antagonists directly block GnRH receptors, causing an immediate decrease in hormone levels. For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market, request a sample here

The Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market major growth driver - Surge In Ovarian And Prostate Cancers Fueling The Growth Of The Market Due To Rising Life Expectancy And Hormone Sensitivity. For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market, request a sample here

The Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market size has grown strongly in recent years. The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size has grown strongly in recent years. It will grow from $1.57 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing prevalence of hormone-related disorders, rising incidence of prostate and breast cancer, growing awareness about reproductive health, increasing demand for assisted reproductive technologies, and rising adoption of hormone therapies in endometriosis and uterine fibroids. The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing preference for minimally invasive treatments, rising awareness of women’s health issues, growing availability of combination therapies, increasing healthcare access in developing regions, and rising pipeline of innovative formulations. Major trends in the forecast period include advancement in oral GnRH antagonist formulations, innovation in combination therapies with hormonal add-back, integration of digital health tools in reproductive treatment monitoring, advancement in clinical trial designs for faster approvals, and integration of telemedicine in hormone therapy. For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market, request a sample here

The gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market covered in this report is segmented –
1) By Drug Type: GnRH Agonists, Leuprorelin, Goserelin, Triptorelin, Histrelin, Buserelin, GnRH Antagonists, Degarelix, Abarelix, Other Drug Types
2) By Application: Gynecology, Oncology, Other Applications
3) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments:
1) By GnRH Agonists: Deslorelin, Gonadorelin, Zoladex Long-Acting Goserelin Variant, Lupron Depot-Ped, Sustained-Release Microsphere Formulations
2) By Leuprorelin: Depot Injection, Implant, Combination Therapy Formulations
3) By Goserelin: Subcutaneous Implant, Oncology-Specific Formulation, Gynecology-Specific Formulation
4) By Triptorelin: Intramuscular Injection, Long-Acting (1-, 3-, 6-Month) Depot, Fertility Treatment Formulation
5) By Histrelin: Subcutaneous Implant, Pediatric (Precocious Puberty) Formulation, Adult Prostate Cancer-Specific Version
6) By Buserelin: Nasal Spray, Subcutaneous Injection, In Vitro Fertilization And Fertility Cycle Formulations
7) By GnRH Antagonists: Teverelix DP, Elagolix, Relugolix, Ganirelix, Linzagolix
8) By Degarelix: Subcutaneous Injection, Monthly Dosing, Prostate Cancer-Specific Formulation
9) By Abarelix: Intramuscular Injection, Advanced Prostate Cancer, Short-Acting Formulation
10) By Other Drug Types: Subcutaneous Injection, In Vitro Fertilization-Specific Use, Multiple Dosing Regimens For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market,
request a sample here

North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market, request a sample here.

Major companies operating in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market are Pfizer Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Intas Pharmaceuticals Limited, Sumitomo Pharma Co. Ltd., Ipsen S.A., Dr. Reddy's Laboratories Limited, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Zydus Lifesciences Limited, Gland Pharma Limited, Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Aska Pharmaceutical Co. Ltd., Ferring International Center S.A., Tolmar Inc., Debiopharm International SA, TerSera Therapeutics LLC, TiumBio Co. Ltd. . For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market, request a sample here.

Major trends in the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market include Companies Drive Innovation With Oral GnRH Antagonists To Enhance Prostate Cancer Treatment. For further insights on the Gonadotropin Releasing Hormone GnRH Agonists And Antagonists Drugs market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon